New peptide drug hopes to boost stroke recovery
NCT ID NCT07581210
First seen May 19, 2026
Summary
This study tests an experimental drug called QD202 in people who have had a stroke caused by a blood clot (acute ischemic stroke) and received clot-busting treatment. The drug is designed to cross into the brain and protect nerve cells. About 120 participants will receive either QD202 or a placebo daily for five days, and researchers will monitor their safety and recovery over 90 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Benxi Central Hospital
RECRUITINGBenxi, Liaoning, China
Contact Email: •••••@•••••
Contact
-
Central Hospital Affiliated to Shenyang Medical College
RECRUITINGShengyang, Liaoning, China
Contact Email: •••••@•••••
Contact
-
General Hospital of Fuxin Mining Industry Group of Liaoning Health Industry Group
RECRUITINGFuxin, Liaoning, China
Contact Email: •••••@•••••
Contact
-
General Hospital of Northern Theater Command
RECRUITINGShenyang, Liaoning, China
Contact Email: •••••@•••••
Contact
-
Huashan Hospital Fudan University
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Contact
Contact Email: •••••@•••••
Contact
-
Jilin Province People's Hospital
RECRUITINGChangchun, Jilin, China
Contact Email: •••••@•••••
Contact
-
Linfen Central Hospital
RECRUITINGLinfen, Shanxi, China
Contact Email: •••••@•••••
Contact
-
Linyi People's Hospital
RECRUITINGLinyi, Shandong, China
Contact Email: •••••@•••••
Contact
-
Luoyang Central Hospital
RECRUITINGLuoyang, Henan, China
Contact Email: •••••@•••••
Contact
-
Meihe Hospital the First Hospital of Jilin University
RECRUITINGMeihekou, Jilin, China
Contact Email: •••••@•••••
Contact
-
Meizhou People's Hospital
RECRUITINGMeizhou, Guangdong, China
Contact Email: •••••@•••••
Contact
-
Nanshi Hospital of Nanyang
RECRUITINGNanyang, Henan, China
Contact Email: •••••@•••••
Contact
-
Shanghai Tenth People's Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact Email: •••••@•••••
Contact
-
Weifang People's Hospital
RECRUITINGWeifang, Shandong, China
Contact Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QD202 (a peptide that crosses the blood-brain barrier to potentially protect brain cells)
What this could lead to
If successful, this could point toward a new treatment to improve recovery and reduce disability after a stroke.
What could go wrong
This is an early Phase 2 trial with only 120 participants, so results may not apply to all stroke patients. The drug may not prove effective or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.